Results 191 to 200 of about 3,425,228 (311)

Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and Mendelian randomization analysis. [PDF]

PLoS Med
Alcala K, Mariosa D, Jacobson S, Coscia-Requena C, Dimou N, Franklin O, Martin RM, Smith GD, Gunter MJ, Brennan P, Pollak M, Langdon R, Johansson M.   +12 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes. [PDF]

J Natl Cancer Inst
Abubakar M, Duggan MA, Fan S, Pfeiffer RM, Lawrence S, Mutreja K, Klein A, Koka H, Ahearn TU, Henry JE, Sprague BL, Vacek PM, Weaver DL, Richert-Boe K, Kimes TM, Titiloye N, Edusei L, Figueroa JD, Yang XR, Garcia-Closas M, Rohan TE, Gierach GL.   +21 more
europepmc   +1 more source

Cancer Etiology [PDF]

, 2020
openaire   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Cross-tissue transcriptome-wide analysis reveals novel insights into thyroid cancer etiology. [PDF]

Discov Oncol
Zhu Y, Luo Y, Zhang Y, Wang Y, Gu Z, Liu J, Qin A, Qian W.   +7 more
europepmc   +1 more source

Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities study. [PDF]

Int J Cancer, 2020
John EM, Phipps AI, Hines LM, Koo J, Ingles SA, Baumgartner KB, Slattery ML, Wu AH.   +7 more
europepmc   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source

Correction: Knowledge of Thai women in cervical cancer etiology and screening. [PDF]

PLoS One
Khomphaiboonkij U, Sreamsukcharoenchai N, Pitakkarnkul S, Rittiluechai K, Tangjitgamol S, Thai Gynecologic Cancer Research Group.   +5 more
europepmc   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source